Percutaneous radiofrequency ablation for primary and secondary lung cancers
Summary
The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Percutaneous radiofrequency ablation for primary and secondary lung cancers.
Description
Both primary lung cancer, and metastatic lung disease are common. The stage of the disease is the most important prognostic factor; however, the overall prognosis for patients with lung cancer is poor. Percutaneous radiofrequency ablation may be used in patients with small early-stage lung cancer for whom surgery is not appropriate or who do not wish to undergo conventional surgery, and for patients with a small number of lung metastases
A small needle electrode is inserted through the skin directly into the tumour, usually under computed tomography (CT) guidance. Radiofrequency energy is passed through the electrode, producing heat which destroys the tumour tissue.
OPCS code:
Details
Respiratory
British Society of Interventional Radiology
Royal College of Radiologists
British Thoracic Society
Society of Cardiothoracic Surgeons of GB & Ireland
Contact details:
(for general enquiries or comments)
(for procedure specific enquiries or comments)
ip@nice.org.uk
Interventional Procedures Programme
National Institute for Health and Clinical Excellence
MidCity Place
71 High Holborn
London
WC1V 6NA
